BMJ Open Accuracy of administrative databases in detecting primary breast cancer diagnoses: a systematic review

Iosief Abraha,^{1,2} Alessandro Montedori,¹ Diego Serraino,³ Massimiliano Orso,^{1,2} Gianni Giovannini,¹ Valeria Scotti,⁴ Annalisa Granata,⁵ Francesco Cozzolino,¹ Mario Fusco,⁵ Ettore Bidoli³

To cite: Abraha I, Montedori A, Serraino D, *et al.* Accuracy of administrative databases in detecting primary breast cancer diagnoses: a systematic review. *BMJ Open* 2018;**8**:e019264. doi:10.1136/bmjopen-2017-019264

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-019264>).

Received 21 August 2017

Revised 8 May 2018

Accepted 11 June 2018

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Health Planning Service, Regional Health Authority of Umbria, Perugia, Italy

²Innovation and Development, Agenzia Nazionale per i Servizi Sanitari Regionali (Age.Na.S.), Rome, Italy

³Cancer Epidemiology Unit, IRCCS Centro di Riferimento Oncologico Aviano, Aviano, Italy

⁴Center for Scientific Documentation, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

⁵Registro Tumori Regione Campania, ASL Napoli 3 Sud, Brusciano, Italy

Correspondence to

Dr Alessandro Montedori; amontedori@regione.umbria.it

ABSTRACT

Objective To define the accuracy of administrative datasets to identify primary diagnoses of breast cancer based on the International Classification of Diseases (ICD) 9th or 10th revision codes.

Design Systematic review. Data sources: MEDLINE, EMBASE, Web of Science and the Cochrane Library (April 2017).

Eligibility criteria The inclusion criteria were: (a) the presence of a reference standard; (b) the presence of at least one accuracy test measure (eg, sensitivity) and (c) the use of an administrative database.

Data extraction Eligible studies were selected and data extracted independently by two reviewers; quality was assessed using the Standards for Reporting of Diagnostic accuracy criteria.

Data analysis Extracted data were synthesised using a narrative approach.

Results From 2929 records screened 21 studies were included (data collection period between 1977 and 2011). Eighteen studies evaluated ICD-9 codes (11 of which assessed both invasive breast cancer (code 174.x) and carcinoma in situ (ICD-9 233.0)); three studies evaluated invasive breast cancer-related ICD-10 codes. All studies except one considered incident cases. The initial algorithm results were: sensitivity $\geq 80\%$ in 11 of 17 studies (range 57%–99%); positive predictive value was $\geq 83\%$ in 14 of 19 studies (range 15%–98%) and specificity $\geq 98\%$ in 8 studies. The combination of the breast cancer diagnosis with surgical procedures, chemoradiation or radiation therapy, outpatient data or physician claim may enhance the accuracy of the algorithms in some but not all circumstances. Accuracy for breast cancer based on outpatient or physician's data only or breast cancer diagnosis in secondary position diagnosis resulted low.

Conclusion Based on the retrieved evidence, administrative databases can be employed to identify primary breast cancer. The best algorithm suggested is ICD-9 or ICD-10 codes located in primary position.

Trial registration number CRD42015026881.

INTRODUCTION

The burden of cancer is increasingly growing among populations, and it is associated with major economic expenditure worldwide,¹

Strengths and limitations of this study

- Based on a prepublished protocol, this is the first review that systematically addressed the accuracy of administrative databases in identifying subjects with breast cancer.
- We performed a comprehensive electronic databases search complemented with reference check of relevant articles, and we evaluated the quality of reporting of included studies by the Standards for Reporting of Diagnostic checklist.
- We considered only papers written in English and this might have introduced a language bias.
- The knowledge and experience of the International Classification of Diseases (ICD)-9/ICD-10 coders could have influenced the quality of breast cancer case definition in each study, and consequently the results presented in our review could be biased by this factor.
- Generalisability of validated administrative databases is limited to the context in which they are generated.

especially in low-income and middle-income countries.²

As breast cancer is the most common cancer and the leading cause of cancer death in women,³ knowledge of its epidemiology and the ability to monitor related outcomes over time is important for health planning services. Administrative health-care databases are increasingly being used in oncology for epidemiological evaluation,⁴ population outcome research,⁵ drug utilisation reviews,^{6–8} evaluation of health service delivery and quality^{9 10} as well as health policy development.^{11–13} Generally, these databases gather longitudinal information concerning health resource utilisation regarding hospitalisations, outpatient care and, often, drug prescriptions and vital statistics.¹⁴ In other words, these databases provide a readily available source of ‘real-world’ data on a large population of unselected patients allowing

the performance of less expensive and more representative assessment of disease surveillance and outcome research compared with randomised trials.^{15 16}

By definition, administrative healthcare databases contain data that are routinely and passively collected without an a priori research question, as they are usually established for billing or, in general, for administrative purposes, and not for research uses. Hence, the diagnostic codes used to identify, for example, cancers, must be validated according to an accepted 'reference standard' diagnosis.¹⁷ In validation studies of administrative databases, the reference standard usually used is the clinical chart or cancer registry.¹⁸

The current *International Classification of Diseases, 9th revision*, (ICD-9) codes are 233.0 for breast carcinoma in situ and 174.0–174.9 for invasive breast cancer, whereas the ICD-10 codes are D05.0–D05.9 and C50.0–C50.9, respectively. These codes help to identify subjects that have breast cancer within an administrative healthcare database. Since the clinical diagnosis of breast cancer is based on a combination of clinical and/or instrumental examinations and a pathological assessment,¹⁹ these codes are limited in confirming whether a specific subject within the databases truly has the disease of interest. As a result, researchers have proposed a number of different claim-based algorithms for case identification of breast cancers, such as a combination of healthcare claims data,²⁰ the use of chemotherapy²¹ and the number of medical claims on separate dates.¹¹ In addition, since patients with metastatic cancer have different prognoses and typically different treatment patterns to those with earlier-stage malignancies, researchers suggest using algorithms to identify patients with metastatic cancer.^{11 22}

To our knowledge, data on the validity of breast cancer diagnosis codes have not been synthesised in the medical literature. Our objective was to determine the best algorithms with which to identify breast cancer cases using administrative databases based on a comprehensive systematic search of primary studies that validated ICD-9 or ICD-10 codes related to breast cancer. The present work has been conceived within a project of validating three large administrative healthcare databases in Italy concerning ICD-9-CM codes for breast, colorectal and lung cancers.^{23–25} For our purposes, it was important to identify all available case definitions or algorithms that best identify subjects with the cancer diseases of interest as outlined in our protocol.²⁶

METHODS

This study is part of different projects supported by national and local funding with the objectives of assessing case definitions of diseases as well as validating ICD-9 codes for cancer^{23 26} and other diseases.^{27–29}

As outlined in the protocol,²⁶ the target population consisted of patients with primary diagnosis of breast cancer, the index test was represented by administrative data algorithms related to breast cancer, the reference

standard was represented by medical charts, validated electronic health records or cancer registries.

Literature search

Comprehensive searches of MEDLINE, EMBASE, Web of Science and the Cochrane Library from their inception to April 2017 were performed to identify published peer-reviewed literature. We developed a search strategy based on the combination of: (a) keywords and Medical Subject Heading (MeSH) terms to identify records concerning breast cancer; (b) terms to identify studies likely to contain validity or accuracy measures and (c) a search strategy designed to capture studies that used healthcare administrative databases based on the combination of terms used by Benchimol *et al*³⁰ and the Mini-Sentinel's program.^{31 32} The developed search strategy is reported in the online supplementary file 1. To retrieve additional articles, the authors searched relevant reference lists of key articles. Titles and abstracts were screened for eligibility by two independent reviewers. Discrepancies were solved by discussion.

This systematic review was prepared according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis Protocols (PRISMA-P) 2015 Statement³³ and the results were presented following the PRISMA flow diagram (figure 1).³⁴ A protocol of this review has also been published at the *BMJ Open*²⁶ as well as an outline in the PROSPERO International Prospective Register of systematic reviews with registration number CRD42015026881 (<http://www.crd.york.ac.uk/PROSPERO>).

Inclusion criteria

Full texts of eligible peer-reviewed articles without publication date restriction, published in English that used administrative data for the ICD-9 or ICD-10 codes related to breast cancer diagnoses were obtained. For each study, the following inclusion criteria were applied: (a) the presence of a reference standard (clinical chart, cancer registry or electronic health records), together with the presence of any case definition or algorithm for breast cancer; (b) the presence of at least one test measure (eg, sensitivity, positive predictive value (PPV), etc); (c) the data source was from an administrative database (ie, a database in which data are routinely and passively collected without an a priori research question) and (d) the study database was from a representative sample of the general population.

We aimed to focus on primary diagnosis of breast cancers, hence studies that considered algorithms to identify cancer history, cancer progression or recurrence were not evaluated.

In addition, studies that considered index test databases that were not truly administrative (eg, cancer registries, epidemiology surveillance systems, etc) were excluded. However, studies that used electronic health records to validate breast cancer were also included.^{35 36}

Figure 1 Study screening process.

Selection process

After screening titles and abstracts, we subsequently obtained full texts of eligible articles to determine if they meet the inclusion and exclusion criteria. We conducted data abstraction using standardised data collection forms that were tested on a sample of three eligible articles. Two review authors working independently and in duplicate were involved in titles and abstracts screening, full-texts screening and data abstraction (FC, MO, AG, VS). Discrepancies were resolved by consensus, and where necessary with the involvement of a third review author (IA). Calibration exercises were performed at each level of the process.

Data extraction

Data extraction included the following information: the details of the included study (including title, year and journal of publication, country of origin and sources of funding; the type of disease (invasive, in situ or both); the

target population from which the administrative data were collected; the type of administrative database used (eg, hospitalisation discharge data), outpatient records (eg, physician billing claims); the ICD-9 or ICD-10 codes used or the administrative data algorithms tested (including Current Procedural Terminology; prescription fills, etc); the position of the ICD codes in the discharge abstract database (ICD codes in primary position indicate the principal diagnosis, that is, the condition identified at the end of the admission, which is the main cause of the need for treatment or diagnostic investigations; ICD codes in secondary positions refer to secondary diagnoses, that is, conditions that coexist at the time of the admission or which develop after that time and which influence the treatment received and/or the length of hospital stay); the modality of development of the algorithm (eg, using Classification and Regression Trees, logistic regression, expert opinion, etc); external validation; use of training

and testing cohorts; the reference standard used to determine the validity of the diagnostic codes (eg, medical chart review, patient self-reports, cancer registry, etc); the characteristic of the test used to determine the validity of the diagnostic code or algorithm (eg, sensitivity, specificity, PPVs and negative predictive values (NPVs), area under the receiver operating characteristic curve, likelihood ratios and kappa statistics).

Quality assessment

The design and methods of the included primary studies were assessed using a checklist developed by Benchimol *et al.*,³⁰ based on the criteria published by the Standards for Reporting of Diagnostic accuracy (STARD) initiative for the accurate reporting of studies using diagnostic studies.³⁷ The checklist is provided in online supplementary file 2. The presence of potential biases within the studies were reported in a descriptive way.

Analysis

For each algorithm, we abstracted the performance statistics provided in the included studies including sensitivity, specificity, PPV and NPV. Where necessary, we calculated validation statistics together with their 95% CIs as far as raw numbers for cases and controls were provided.

Patient and public involvement

Patients and the public were not directly involved. This was a retrospective study based on the consultation of electronic medical literature.

RESULTS

Literature search

After removing duplicate records identified through MEDLINE, EMBASE, Web of Science and The Cochrane Library, 2929 citations were screened in titles and abstracts. Overall, we assessed 41 full-text articles for eligibility, of which 17^{10 38–53} were included in the final evaluation. In addition, a reference check of pertinent articles permitted the identification of five potentially relevant studies of which four were included in the final analysis^{54–57} (figure 1). The list of excluded studies, together with the reasons of their exclusion is reported in the online supplementary file 3.

Study characteristics

The included studies were published between 1992 and 2015 and collected data between 1977 and 2011. Fifteen studies were performed in the USA,^{39 41 42 44–47 51–53 55–59} two were conducted in Italy,^{10 38} two in France,^{40 54} one in Japan⁴⁹ and one in Australia.⁴³ Seventeen studies used Cancer Registry data as the reference standard,^{38–40 42 43 45–47 49–57 60} four studies used medical chart review.^{45 50 51 57}

Eighteen studies^{10 38 39 41 42 44–48 50–57} evaluated ICD-9 codes, and three studies^{40 43 49} evaluated ICD-10 codes. Of the studies that evaluated ICD-9 codes, 11 reported the evaluation of the ICD-9 codes related to invasive breast cancer (code 174.x) and carcinoma in situ

(ICD-9 233.0)^{10 38 42 44–47 50–53}; three evaluated only invasive cancer (ICD-9 174.x)^{39 41 55}; three studies did not specify the number of the ICD-9 codes evaluated.^{54 56 57} Three studies evaluated ICD-10 codes for invasive breast cancer without evaluating carcinoma in situ codes.^{40 43 49}

In terms of representativeness or generalisability, the studies varied greatly. Eight studies considered all women beneficiaries of the Medicare programme, USA), age 65 years or above residing in specific areas,^{39 42 46 51–53 55 56} nine studies considered all women with any age^{38 49} or aged 15+⁵⁴ or 20+^{10 38 40 45 50 57} in specific areas, two studies considered all women aged 40+⁴⁴ or 45+⁴³ residing in specific areas and three studies randomly sampled residents at a national level,⁴¹ or residents at regional level.^{47 59}

Basic characteristics of these studies are displayed in table 1.

Validity of breast cancer data

Accuracy results by initial algorithms

All the studies considered new (incident) breast cancer cases except Fisher *et al.*⁴¹ Nineteen studies presented the initial accuracy results based on breast cancer diagnosis only; in 18 studies the diagnosis was in primary position,^{10 38–50 52–54 56} in 1 study in any position⁵⁵ and in 2 studies the position was unclear,^{51 57} whereas 2 studies evaluated breast cancer diagnosis with surgical procedures.^{10 38}

Sensitivity was reported by 17 studies, and was at least 80% in 65% (n=11) of them^{10 41 43 44 46 47 49 53–55 57} (range 57%–99%). PPV, obtained from 19 studies, was ≥83% in the majority (n=14) of them (range 15%–98%). Specificities resulted higher than 98% in all the eight studies that provided sufficient data to permit calculation.^{10 40 43 47 49 52 54 56} Similarly, the NPV for the five studies for which it was possible to calculate was ≥99%.^{40 43 52 54 56} Table 2 displays the results of the algorithm with which the studies presented their initial data stratified by ICD codes.

Accuracy results by combinations of diagnosis and surgical procedures

Twelve studies reported validation results using algorithms with different combinations.^{10 38 40 43–45 49–52 54 56} All algorithms, except in two studies,^{10 38} started evaluating basic breast cancer codes and progressively added surgical procedures, secondary diagnosis, chemotherapy and/or radiotherapy. The addition of one or more of these items to the algorithms produced different results over the basic accuracy results obtained with the use of the diagnosis code alone. The addition of excision to the incident diagnosis of invasive cancer codes did not add any value to the PPV in the studies by Solin *et al.*⁵⁰ (88% vs 89%), Leung *et al.*⁴⁵ (83% vs 84%) and Kemp *et al.*⁴³; conversely, in the study by Solin *et al.*⁵¹ while in the first algorithm there were no improvements between the new diagnosis and the addition of the excision (83% vs 84%), using the best algorithm set, the PPV rose from 84% to 92% when excision was added to

Table 1 Characteristics of included studies

First author, year of publication	Period of data collection	Country	Records evaluated (N)	Source population	Type of administrative data	Diagnostic codes	Algorithm	Reference standard
Fisher <i>et al</i> ⁴¹ 1992	1984–1985	USA	33 cases (any position); 24 cases (first position) from each 239 hospitals	All National Medical beneficiaries,	Medicare claim database: inpatient hospital discharge.	174–174.9	(a) Diagnosis in any position. (b) Diagnosis in primary position.	Medical records review
McBean <i>et al</i> ⁵⁵ 1994	1986–1987	USA	5744 cases	Persons 65 years of age and older living in the five states participating in the SEER Program.	Medicare claim database: inpatient hospital data.	174–174.9	New cases of breast cancer with diagnostic codes in any position.	Cancer Registry (SEER)
Solin <i>et al</i> ⁵⁰ 1994	1988–1989	USA	469 cases	Women aged ≥21 years enrolled in the USA. Healthcare in the southeastern Pennsylvania region.	Claims database included inpatient hospital stays, short procedure unit stays and professional services. Each claim included the USA (comprised ICD-9 code and CPT-4).	174–174.9; 233.0	(A) Initial algorithm based on new case of breast carcinoma+one or more of the following: (1) mastectomy, (2) partial mastectomy with lymphadenectomy, (3) excision, breast biopsy or partial mastectomy+lymphadenectomy, (4) excision, breast biopsy or partial mastectomy+the diagnosis of carcinoma of the breast, (5) excision, breast biopsy or partial mastectomy followed by radiation therapy treatment or (6) excision, breast biopsy or partial mastectomy followed by chemotherapy treatment. (B) Best algorithm with multiple modifications of the initial algorithm.	Medical records review
Warren <i>et al</i> ⁵³ 1996	1989	USA	3454 cases	All women aged 65+ years with one or more hospitalisations with a diagnosis of breast cancer in Medicare.	Medicare Hospital Inpatient (ICD-9-CM).	174–174.9; 233.0	(i) Any hospitalisation breast cancer (ICD-9-CM 174–174.9 and 233.0) as principal diagnosis. (ii) Incident cases of breast cancer (no prior hospitalisation with breast cancer in any of the 5 positions from 1984 to 1988 or history of breast cancer (ICD-9-CM V.10.3 (ICD-9-CM V.10.3) appearing as any of the five positions from 1984 to 1989). (iii) Analysis limited to women who were residents in one of the five SEER states.	Cancer Registry (SEER)

Continued

Table 1 Continued

First author, year of publication	Period of data collection	Country	Records evaluated (N)	Source population	Type of administrative data	Diagnostic codes	Algorithm	Reference standard
Solin <i>et al</i> ⁵¹ 1997	1993–1994	USA	177 cases	All women aged ≥65 years enrolled in the US Healthcare (Pennsylvania and New Jersey).	Claims database included hospital inpatient, short procedure unit stays and professional services (ICD-9 diagnosis code, and the CPT-4 procedure code).	174–174.9; 233.0	This study was performed to evaluate prospectively a previously published algorithm ³⁰ used to identify women with the new diagnosis of carcinoma of the breast.	Medical records review
McClish <i>et al</i> ⁴⁶ 1997	1986–1989	USA	3690 cases	All residents aged 65+ years diagnosed with breast cancer (Virginia).	MEDPAR (Medicare) inpatient hospital claim database (ICD-9 CM).	174–174.9; 233.0	Incident cases of breast cancer ICD-9-CM 174; V174.9; 233 and 233.0.	Cancer Registry
Cooper <i>et al</i> ⁶¹ 1999	1984–1993	USA	71 862 cases	All women aged 64+ years with breast cancer (Atlanta, Detroit, Seattle-Puget Sound, San Francisco Oakland, Connecticut, Hawaii, Iowa, New Mexico and Utah).	(1) MEDPAR (Medicare: inpatient hospital claim database (ICD-9 CM and specific procedural codes ICD-9-CM and HCPCS/CPT-4. (2) Part B: physician and outpatient claim data.	174–174.9	Basic: incidence breast cancer (174.0–174.9); (i) all other inpatient diagnostic codes; inpatient cancer-specific surgical code (local excision/lumpectomy: 85.20, 85.21, 85.22); Part B: first position diagnosis code; any other part B diagnosis codes and part B cancer-specific surgical code; (ii) first position diagnostic coding+the inclusion of the following: all other part B diagnosis codes; part B cancer-specific procedural code; inpatient first position diagnosis; all other inpatient diagnoses and inpatient cancer-specific surgery.	Cancer Registry (SEER)
Warren <i>et al</i> ⁶² 1999	1992	USA	Women residing in the SEER states n=6 59 260; cases=6784.	All Medicare eligible women residing in one of five SEER states who were age 65 years and older as of 1 January 1992.	Medicare inpatient and physician claim database (ICD-9).	174–174.9; 233.0	Model 1: inpatient primary diagnosis (174–174.9, 233.0), excluding prevalent cases), inpatient-secondary diagnosis, and physician bills—reference group). Model 2: inpatient-secondary diagnosis and cases identified from the physician data, breast cancer-related procedures.	Cancer Registry (SEER)

Continued

Table 1 Continued

First author, year of publication	Period of data collection	Country	Records evaluated (N)	Source population	Type of administrative data	Diagnostic codes	Algorithm	Reference standard
Leung <i>et al</i> ⁴⁵ 1999	1994–1996	USA	1033 cases	All women aged 21 years or older who were enrolled in Health Net (California).	Claims database includes claims received for inpatient hospital stays, short procedure unit stays and professional services (code ICD-9-CM).	174–174.9; 233.0	Basic breast cancer diagnosis and one of the following: (1) mastectomy; (2) partial mastectomy with lymphadenectomy; (3) excision, breast biopsy or partial mastectomy+lymphadenectomy; (4) excision, breast biopsy or partial mastectomy+diagnosis of carcinoma; (5) excision, breast biopsy or partial mastectomy followed by radiation therapy or (6) excision, breast biopsy or partial mastectomy followed by chemotherapy.	Medical chart review
Freeman <i>et al</i> ⁴² 2000	1990–1992	USA	7464 cases; 1415 controls	Females aged 65–74 years (in 1992) diagnosed with breast cancer (San Francisco/Oakland, Detroit, Atlanta and Seattle and the states of Connecticut, Iowa, New Mexico, Utah and Hawaii).	ICD-9 inpatient record; outpatient record; physician claim (Medicare).	174–174.9; 233.0; V103	Model 1 (6 predictors): hospital inpatient; breast cancer principal or additional diagnosis) or 1992 hospital. Model 2: (10 predictors) (model 1 or breast cancer-related procedure (mastectomy, partial mastectomy, excisional biopsy, incisional biopsy). Model 3 (36 predictors): (hospital inpatient, hospital outpatient, physician claim); model 1 and breast cancer-related procedure (mastectomy biopsy, biopsy, chemotherapy); mammography, breast cancer-related radiology, radiation oncology, laboratory test on a hospital outpatient. Model 4 (hospital inpatient, hospital outpatient, physician claim): model 1 and breast cancer-related procedure (mastectomy biopsy, biopsy, chemotherapy); mammography, breast cancer-related radiology, radiation oncology, laboratory test on a hospital outpatient; biopsy, radiation oncology, laboratory test on a physician claim; mammography, other radiological procedures in 1992 on a hospital outpatient claim.	Cancer Registry (SEER)

Continued

Table 1 Continued

First author, year of publication	Period of data collection	Country	Records evaluated (N)	Source population	Type of administrative data	Diagnostic codes	Algorithm	Reference standard
Wang <i>et al</i> ⁶⁷ 2001	1989–1991	USA	8872 cases	All women aged 20 years and older who were enrolled in either Medicaid or Medicare and PAAD (New Jersey State).	Medicaid in patient files.	ICD-9 code: not reported	New cases of breast cancer: primary algorithm definitions: surgical claims for (a) a CPT or ICD-9 procedure code for a mastectomy; (b) a CPT or ICD-9 procedure code for an excision of a breast mass+CPT or ICD-9 procedure code for an axillary node biopsy; (c) a DRG hospitalisation code for breast cancer surgical hospitalisation. Alternative algorithms: combinations of ICD-9 diagnostic codes, DRG hospitalisation codes, and codes for non-surgical treatments.	Cancer registry
Koroukian <i>et al</i> ⁶⁴ 2003	1997–1998	USA	2635 incident cases	Women aged 40 years or older (Ohio).	Medicaid claims and enrollment files. ICD-9-CM.	174–174.9; 233.0	Incident of breast cancer (ICD-9 174.0–174.9 233.0) and combinations of diagnosis and procedures codes (chemotherapy or radiation therapy, mastectomy, lumpectomy).	Cancer Registry (OCISS)
Ganry <i>et al</i> ⁶⁴ 2003	1998	France	198 incident cases	All women aged 15 years or older who were diagnosed or treated (in the Amiens University Hospital and five general hospitals) of the Somme area.	French hospital database adapted from the Diagnosis Related Group (DRG).	ICD-9 code: not reported	New case of breast cancer—at least one of the following criteria: (a) breast cancer as primary diagnosis, alone or with (i) mastectomy; (ii) partial mastectomy with lymphadenectomy or (iii) excision, breast biopsy or partial mastectomy for procedures; (b) breast cancer as secondary diagnosis, with (i) chemotherapy as principal diagnosis or (ii) without specific procedures (excluding prevalent cases: women with history of breast cancer between 1991 and 1997).	Cancer registry (French Somme Area)
Nattlinger <i>et al</i> ⁶⁷ 2004	Validation set: 1994; training set: 1995	USA	7607 cases and 120 317 controls	Training set: claims from 7700 SEER-Medicare breast cancer subjects (age 65+ years) diagnosed in 1995, and 124 884 controls. Validation set: claims from 7607 SEER-Medicare breast cancer subjects diagnosed in 1994, and 120 317 controls.	Random sample; ICD-9 inpatient record; outpatient record; physician claim (Medicare).	174–174.9; 233.0	Four-step algorithm: (1) breast cancer diagnosis+procedure code; (2) both conditions: (a) mastectomy or a lumpectomy or partial mastectomy followed by at least one outpatient or carrier claim for radiotherapy with a breast cancer diagnosis; (b) at least two outpatient or carrier claims on different dates containing breast cancer as the primary diagnosis; (3) this step applies to all potential cases that passed step 1, but were not directly included at step 2; (4) removal of prevalent cases.	Cancer Registry (SEER)

Continued

Table 1 Continued

First author, year of publication	Period of data collection	Country	Records evaluated (N)	Source population	Type of administrative data	Diagnostic codes	Algorithm	Reference standard
Penberthy <i>et al</i> ⁵⁹ 2005	1995	USA	249 cases	Women aged 65+ years with breast cancer diagnosis.	(a) Inpatient Medicare; (b) inpatient or Part B claims.	ICD-9 174	Six case definitions: A1) diagnosis first position; A2) inpatient diagnosis in any position; A3) inpatient diagnosis in any position+inpatient surgical procedure; B1) inpatient diagnosis in any position+inpatient surgical procedure; B2) inpatient diagnosis in any position+inpatient surgical procedure OR a diagnostic procedure+diagnosis+a surgery or chemotherapy or radiation therapy procedure in an outpatient or physician office record within 4 months of a diagnostic procedure; B3) inpatient diagnosis in any position OR a diagnosis+a surgery or chemotherapy or radiation therapy procedure in an outpatient or physician office record.	Cancer Registry (Virginia State); medical chart review
Setoguchi <i>et al</i> ⁵⁶ 2007	1997–2000	USA	2004 cases	Subjects aged 65+ years Medicare recipients in Pennsylvania.	Medicare inpatient hospital claim and drug benefit programme data.	Unclear	Four algorithms based on the combination of the following: (a) ICD-9 diagnosis codes (<i>numbers not provided</i>), (b) CPT codes for screening procedures, surgical procedures, radiation therapy, chemotherapy and nuclear medicine procedures and/or (c) National Drug Code prescription codes for medications used for cancer treatment available in Pharmaceutical Assistance Contract for the Elderly.	Cancer Registry (Pennsylvania State)
Baldi <i>et al</i> ³⁸ 2008	2000 training set, 2001 validation set	Italy	925 cases	All residents in Piedmont region.	Regional inpatient administrative database.	174–174.9; 233.0	Algorithms based on combination between (i) ICD-9-CM diagnosis breast cancer (invasive 174.0–174.9, in situ 233.0); and ICD-9-CM procedures code incisional breast biopsy: 85.12 excision or destruction of breast tissue: 85.20–85.25 subcutaneous mastectomy: 85.33–85.36 mastectomy: 85.41–85.48	Cancer Registry (Piedmont Region)
Couris <i>et al</i> ⁴⁰ 2009	2002	France	995 cases	Women aged 20 years or older living in one of the nine French districts covered by a cancer registry in 2002.	Inpatient hospital administrative data (French National Institute of Statistics and Economic Studies) based on ICD-10.	C50.0 to C50.9	(a) Principal diagnosis for invasive breast cancer – ICD-10 codes C50.0 to C50.9; (b) principal diagnosis+specific surgery procedures.	French cancer registries

Continued

Table 1 Continued

First author, year of publication	Period of data collection	Country	Records evaluated (N)	Source population	Type of administrative data	Diagnostic codes	Algorithm	Reference standard
Yuen <i>et al</i> ¹⁰ 2011	2002–2005	Italy	11 615 cases	Women aged 20 years older with incident breast cancer (Emilia-Romagna region).	Regional administrative database (Hospital discharge files).	174–174.9; 233.0	Women having a diagnosis code for cancer as well as a principal or secondary surgical code for lumpectomy or mastectomy; principal or secondary procedure indicating excision or destruction of breast tissue (ICD-9-CM code 85.20–85.25) or mastectomy (ICD-9-CM code 85.41–85.48); and principal or secondary diagnosis of carcinoma in situ of the breast (ICD-9-CM code 233.0) or malignant neoplasm of the breast (ICD-9-CM code 174.0–174.9).	Cancer registry (AIRTUM)
Kemp <i>et al</i> ⁴³ 2013	2004–2008	Australia	2039 women with invasive breast tumour	Women aged 45+ years who had completed breast cancer-related items in the baseline survey of the 45 and up study (New South Wales).	i) Administrative hospital separations records (ICD-10-AM); ii) outpatient medical service claims; iii) prescription medicines claims and iv) the 45 and up study baseline survey.	C50.0 to C50.9	Principal inpatient diagnosis of invasive breast cancer using ICD-10-AM codes C50.0–C50.9.	Cancer Registry
Sato <i>et al</i> ⁴⁹ 2015	2011	Japan	50 056 women included in the study cohort (633 with breast cancer)	Women with no prior cancer-related history, from the claims data at a single institution between 1 January and 31 December 2011.	ICD for oncology, third edition (ICD-O-3): topography code of breast cancer (C500 to C506, C508, C509).	C50.0 to C50.9	14 definitions starting from (1) breast cancer alone and subsequent addition of (2) diagnosis code related to breast cancer (3) diagnostic imaging code (4) biopsy code (5) marker test code (6) surgery code (7) chemotherapy code (8) medication code (9) radiation procedure code (10) the other code related to breast cancer (11) diagnosis code related to breast cancer or marker test code (12) surgery, chemotherapy, medication or radiation procedure code (13) diagnosis code related to the breast cancer, marker test code, surgery, chemotherapy, medication or radiation procedure code (14) ≥3 diagnoses of breast cancer.	Cancer Registry

AIRTUM, Associazione Italiana dei Registri Tumori; CPT-4, current procedural terminology-4; HCPCS, Healthcare Common Procedure Coding System; ICD, International Classification of Diseases; MEDPAR, Medicare Annual Demographic Files, the Medicare Provider Analysis and Review; OCIS, Ohio Cancer Incidence Surveillance System; SEER, Surveillance, Epidemiology, and End Results Program.

Table 2 Accuracy results by initial algorithm in the 21 included studies

Study ID	Initial algorithm	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
ICD-9					
Fisher <i>et al</i> ⁴¹ 1992	BCD in primary position	96 (79 to 100)		88 (70 to 98)	
McBean <i>et al</i> ⁵⁵ 1994	BCD in any position	97		96	
Solin <i>et al</i> ⁵⁰ 1994	BCD in primary position			88 (85 to 91)	
Warren <i>et al</i> ⁵³ 1996	BCD in primary position	94 (93 to 95)	97	83 (78 to 89)	
McClish <i>et al</i> ⁴⁶ 1997	BCD in primary position	83 (82 to 84)		91 (90 to 93)	
Solin <i>et al</i> ⁵¹ 1997	BCD (unclear position)			83 (77 to 87)	
Leung <i>et al</i> ⁴⁵ 1999	BCD in primary position			84 (82 to 87)	
Warren <i>et al</i> ⁵² 1999	BCD in primary position	57 (55 to 59)	99 (99 to 99)	91 (90 to 93)	99 (98 to 100)
Cooper <i>et al</i> ⁶¹ 1999	BCD in primary position	68 (68 to 69)			
Freeman <i>et al</i> ⁴² 2000	BCD in primary position	68 (66 to 70)		74 (72 to 76)	
Wang <i>et al</i> ⁵⁷ 2001	BCD (unclear position)	89 (88 to 90)			
Koroukian <i>et al</i> ⁴⁴ 2003	BCD in primary position	69 (66 to 71)		15 (13 to 17)	
Ganry <i>et al</i> ⁵⁴ 2003	BCD in primary position	85 (80 to 90)	100 (100 to 100)	98 (94 to 99)	100 (100 to 100)
Nattinger <i>et al</i> ⁴⁷ 2004	BCD in primary position	80 (79 to 81)	100 (100 to 100)	89 (87 to 92)	
Penberthy <i>et al</i> ⁵⁹ 2005	BCD in primary position	53		96	
Setoguchi <i>et al</i> ⁵⁶ 2007	≥1 BCD in primary position	87 (86 to 89)	100 (100 to 100)	50 (49 to 52)	100 (100 to 100)
Baldi <i>et al</i> ³⁸ 2008	BCD in primary position+surgical procedures	74 (71 to 77)		90 (87 to 92)	
Yuen <i>et al</i> ¹⁰ 2011	BCD in primary position+surgical procedures	85 (84 to 86)	99 (99 to 99)	91 (90 to 91)	
ICD-10					
Couris <i>et al</i> ⁴⁰ 2009	BCD in primary position	69 (66 to 72)	99 (99 to 99)	57 (54 to 60)	100 (100 to 100)
Kemp <i>et al</i> ⁴³ 2013	BCD in primary position	86 (85 to 88)	99 (99 to 99)	86 (84 to 87)	100 (100 to 100)
Sato <i>et al</i> ⁴⁹ 2015	BCD in primary position	99 (98 to 100)	99 (93 to 99)	66 (63 to 69)	

BCD, breast cancer diagnosis; ICD, International Classification of Disease; NPV, negative predictive value; PPV, positive predictive value.

the basic breast diagnosis code. In the study by Koroukian *et al*,⁴⁴ the addition of mastectomy or mastectomy/lumpectomy significantly raised the PPV from 15% to 84% and 87%, respectively. In the study by Kemp *et al*,⁴³ the sensitivity and PPV values of breast cancer diagnosis remained substantially unchanged with the addition of mastectomy, lumpectomy or both (PPV 86% vs 89%). Setoguchi *et al*⁵⁶ proposed four algorithms: the algorithm based on one or more diagnoses of breast cancer generated a sensitivity of 87% and a PPV of 50%; the addition of any surgical procedure lowered the sensitivity to 46% but enhanced the PPV to 82%. In the study by Sato *et al*,⁴⁹ the addition of any code related to breast cancer, marker tests, surgical procedures, chemotherapy treatment or radiation therapy did not affect the sensitivity (that resulted high: 98%) but raised the PPV from 66% to 83%. Similarly in the study by Ganry *et al*,⁵⁴ the addition of any breast or lymph nodal surgical procedures enhanced the PPV from 91% to 98%. Table 3 shows the sensitivities and PPVs with the respective CIs of the studies that in addition to accuracy measures of breast cancer diagnosis also reported accuracy data of surgical procedures.

Accuracy results by combinations of diagnosis and surgical procedures followed by chemoradiation or radiation therapy

Six studies added chemotherapy or radiation therapy procedures to their algorithm.^{44 45 49–51 54} Compared with the initial algorithm with only the diagnosis of breast cancer, the PPV value increased in all instances to values higher than 94% in four studies.^{45 50 51 54} However, in all studies except one the algorithms contained surgical procedures. Table 4 displays the sensitivity and PPV values for the studies that combined chemoradiation or radiation therapy procedures with diagnosis of breast cancer.

Accuracy results based on the position of the diagnosis

Three studies provided results based on the position of the diagnosis.^{41 52 54} Fisher *et al*⁴¹ provided sensitivity and PPV for breast cancer diagnosis in any position and it resulted in similar results in the primary position (sensitivity 97% and PPV 84% in any position; sensitivity 96% and PPV 88% in the primary position). Accuracy results for secondary position breast cancer diagnosis was provided by two studies and the estimates resulted lower than the accuracy results for diagnosis in primary position in the studies by Ganry *et al*⁵⁴ and Warren *et al*

Table 3 Results of studies validating diagnoses of breast cancer (first row) and surgical procedures (subsequent rows)

#	Author/year	Algorithms invasive breast cancer	Sensitivity	Specificity	PPV	NPV
1	Solin <i>et al</i> ⁶⁰ 1994	Diagnosis incident cases	–	–	88 (85 to 91)	–
2	Solin 1994	Mastectomy	–	–	95 (92 to 98)	–
3	Solin 1994	Partial mastectomy with lymphadenectomy	–	–	96 (91 to 100)	–
4	Solin 1994	Excision and lymphadenectomy	–	–	100 (100 to 100)	–
1	Solin <i>et al</i> ⁶¹ 1997	Initial algorithm: diagnosis incident cases	–	–	83 (78 to 89)	–
2	Solin 1997	Initial algorithm: mastectomy	–	–	95 (90 to 100)	–
3	Solin 1997	Initial algorithm: partial mastectomy with lymphadenectomy	–	–	95 (88 to 100)	–
4	Solin 1997	Initial algorithm: excision and lymphadenectomy	–	–	92 (83 to 100)	–
5	Solin 1997	Best algorithm: diagnosis incident cases	–	–	84 (79 to 90)	–
6	Solin 1997	Best algorithm: mastectomy	–	–	82 (76 to 88)	–
7	Solin 1997	Best algorithm: partial mastectomy with lymphadenectomy	–	–	84 (78 to 89)	–
8	Solin 1997	Best algorithm: excision and lymphadenectomy	–	–	84 (78 to 89)	–
1	McClish <i>et al</i> ⁴⁶ 1997	incident cases identified in MEDPAR	83 (82 to 84)	–	–	–
2	McClish 1997	incident cases identified in VCR	82 (81 to 83)	–	–	–
3	McClish 1997	aggregated (VCR+MEDPAR)	97 (96 to 97)	–	–	–
4	McClish 1997	MEDPAR definitive surgical therapy	80 (79 to 81)	–	–	–
5	McClish 1997	VCR definitive surgical therapy	87 (86 to 88)	–	–	–
1	Leung <i>et al</i> ⁴⁵ 1999	Initial algorithm: diagnosis	–	–	84 (82 to 87)	–
2	Leung 1999	Mastectomy	–	–	92 (90 to 95)	–
3	Leung 1999	Partial mastectomy with lymphadenectomy	–	–	98 (96 to 100)	–
4	Leung 1999	Excision, breast biopsy or partial mastectomy plus lymphadenectomy	–	–	92 (87 to 98)	–
1	Cooper <i>et al</i> ⁶¹ 1999	First set of analysis (increase in SE including in order inpatient other diagnosis, surgical, part B, etc): inpatient, first position diagnostic codes	68 (68 to 69)	–	–	–
2	Cooper 1999	First set of analysis: inpatient, surgical	79 (79 to 79)	–	–	–
3	Cooper 1999	First set of analysis: part B, first position	91 (91 to 91)	–	–	–
4	Cooper 1999	First set of analysis: part B, surgical	94 (93 to 94)	–	–	–
5	Cooper 1999	Second set of analysis (increase in SE including in order part B other diagnosis, surgical, inpatient, etc): part B, first position	66 (66 to 66)	–	–	–
6	Cooper 1999	Second set of analysis: part B, other diagnostic codes	77 (77 to 77)	–	–	–
7	Cooper 1999	Second set of analysis: part B, surgical	81 (81 to 81)	–	–	–
8	Cooper 1999	Second set of analysis: inpatient, first position	91 (91 to 91)	–	–	–
9	Cooper 1999	Second set of analysis: inpatient, surgical	94 (93 to 94)	–	–	–
1	Freeman <i>et al</i> ⁴² 2000	Primary diagnosis: hospital inpatient in Medicare Provider Analysis (MEDPAR)	68 (66 to 70)	–	74 (72 to 76)	–
2	Freeman 2000	Mastectomy hospital inpatient	53 (51 to 56)	–	73	–

Continued

Table 3 Continued

#	Author/year	Algorithms invasive breast cancer	Sensitivity	Specificity	PPV	NPV
3	Freeman 2000	Partial mastectomy hospital inpatient	7 (4 to 11)	–	64	–
4	Freeman 2000	Excisional biopsy hospital inpatient	8 (5 to 12)	–	56	–
5		Incisional biopsy hospital inpatient	8 (5 to 11)	–	73	–
1	Ganry <i>et al</i> ⁵⁴ 2003	Hospitalisation with breast cancer as primary diagnosis: mastectomy	–	–	100 (100 to 100)	–
2	Ganry 2003	Hospitalisation with breast cancer as primary diagnosis: partial mastectomy with lymphadenectomy	–	–	100 (100 to 100)	–
3	Ganry 2003	Hospitalisation with breast cancer as primary diagnosis: biopsy/excision plus the diagnosis of carcinoma	–	–	100 (100 to 100)	–
1	Kemp <i>et al</i> ⁴³ 2013	Diagnosis of invasive breast cancer	86 (85 to 88)	100 (100 to 100)	86 (84 to 87)	100 (100 to 100)
2	Kemp 2013	Lumpectomy	61 (59 to 63)	99 (99 to 99)	52 (50 to 54)	99 (99 to 99)
3	Kemp 2013	Mastectomy	33 (31 to 35)	100 (100 to 100)	71 (68 to 74)	99 (99 to 99)
4	Kemp 2013	Lumpectomy OR mastectomy	84 (83 to 86)	99 (99 to 99)	56 (55 to 58)	100 (100 to 100)

MEDPAR, Medicare Annual Demographic Files, the Medicare Provider Analysis and Review; NPV, negative predictive value; PPV, positive predictive value; VCR, Virginia Cancer Registry.

*al.*⁵² PPVs were 26% and 65% in secondary position against 91% and 91% in primary position, respectively (see online supplementary file 4, eTable 1).

Accuracy results based on outpatient or physician's data

Only two studies assessed the accuracy of breast cancer diagnosis codes based on outpatient or physician's records^{42 52}; the other 19 studies considered inpatient data alone or in combination with other types of data (short procedure unit stays, professional services, prescription medicines claims, etc). For the physician's mammography and laboratory data, the sensitivities resulted 87% in both cases but with very low corresponding PPV values (0% and 15%, respectively).⁴² The remaining cases concerning biopsy, surgical procedures, nodal dissection in the physician records or outpatient records showed very low PPVs (see online supplementary file 4, eTable 2).

Stratified analysis by administrative data source, type of ICD code, country of origin and publication year

Accuracy data stratified by setting of diagnosis showed that outpatient accuracy data were much lower than diagnosis in primary position, although the outpatient accuracy data were reported by only one study.⁴² In terms of codes, both ICD-9 and ICD-10 showed significant variation in both sensitivity and PPV. In terms of country of origin, most of the studies were conducted in the USA where the variability of the accuracy results showed important variation. The studies conducted in Italy^{10 38} and France^{40 54} showed similar ranges of sensitivities, whereas the studies conducted in Italy performed better in terms of PPVs than any other country. Accuracy results of the initial algorithm did not change over time and the range of sensitivities remained similar between the studies published before 2001 compared

with the studies published after 2000. PPVs estimates remained also similar provided one outlier, that is, the study by Koroukian *et al*,⁴⁴ is excluded. Table 5 shows ranges of sensitivities and PPVs stratified by administrative data source, type of ICD code, country of origin and publication year.

Quality of the studies

All the studies explicitly reported their intention to evaluate the accuracy of the administrative database and described validation cohort, age, disease and location of participants. All the studies reported inclusion criteria and only seven^{45 49–51 55 57 59} (33%) did not report exclusion criteria, and three^{52 53 56} (14%) did not report any description regarding the patient sampling method. In terms of the methodology used, all the studies described the methods used to calculate diagnostic accuracy, none of the studies described number, training and expertise of persons reading reference standards; none of the studies reported the consistency and the number of persons involved in reading reference standards and, of the studies that used the medical chart review as the reference standard only one⁴¹ reported the blinding of the interpreters. In terms of statistical methods, all the studies except one⁵⁵ described adequately the statistics used to obtain accuracy. None of the studies reported at least four estimates of diagnostic accuracy. The most common statistics used to estimate diagnostic accuracy were sensitivity in 17 studies^{10 38–41 43 44 46 47 49 52–57 59} (81%), PPV in 19 studies^{10 38 40–47 49–56 59} (90%) and specificity in 9 studies^{10 40 43 47 49 52–54 56} (43%); 10 studies^{10 39 44 46 47 49 50 52 53 57} (48%) reported accuracy results for subgroups; and only 6 studies^{10 38 41 46 47 49} (29%) reported CIs (see online supplementary file 2).

Table 4 Results of studies that combined surgical procedures followed by chemoradiation or radiation therapy with diagnosis of breast cancer

N	Author/year	Algorithms invasive breast cancer	Sensitivity % (CI)	Specificity % (CI)	PPV % (CI)
1	Solin <i>et al</i> ⁵⁰ 1994	Diagnosis incident cases	–	–	88 (85 to 91)
2	Solin 1994	Excision followed by radiation therapy	–	–	94 (88 to 99)
3	Solin 1994	Excision followed by chemotherapy	–	–	94 (88 to 100)
1	Solin <i>et al</i> ⁵¹ 1997	Initial algorithm: diagnosis incident cases	–	–	83 (78 to 89)
2	Solin 1997	Initial algorithm: excision followed by radiation therapy treatment	–	–	97 (91 to 100)
3	Solin 1997	Initial algorithm: excision followed by chemotherapy	–	–	90 (77 to 100)
4	Solin 1997	Best algorithm: diagnosis incident cases	–	–	84 (79 to 90)
5	Solin 1997	Best algorithm: excision followed by radiation therapy treatment	–	–	84 (78 to 89)
6	Solin 1997	Best algorithm: excision followed by chemotherapy	–	–	84 (78 to 89)
1	Leung <i>et al</i> ⁴⁵ 1999	Initial algorithm: diagnosis	–	–	84 (82 to 87)
2	Leung 1999	Excision, breast biopsy or partial mastectomy followed by radiation therapy	–	–	96 (94 to 98)
3	Leung 1999	Excision, breast biopsy or partial mastectomy followed by chemotherapy	–	–	93 (90 to 97)
1	Koroukian <i>et al</i> ⁴⁴ 2003	Incident breast cancer	–	–	15 (13 to 17)
2	Koroukian 2003	Breast cancer diagnosis, chemotherapy or radiation therapy	–	–	34 (29 to 39)
3	Koroukian 2003	Breast cancer diagnosis, lumpectomy, chemotherapy or radiation therapy	–	–	85 (78 to 92)
1	Ganry <i>et al</i> ⁵⁴ 2003	Hospitalisation with breast cancer (primary diagnosis): without any procedure	–	–	91 (81 to 100)
2	Ganry 2003	Hospitalisation with breast cancer (secondary diagnosis): chemotherapy as primary diagnosis	–	–	98 (94 to 100)
1	Sato <i>et al</i> ⁴⁹ 2015	Diagnosis of breast cancer	99 (99 to 100)	99 (93 to 100)	66 (63 to 69)
2	Sato 2015	Diagnosis of breast cancer+diagnosis code related to the breast cancer, marker test code, surgery, chemotherapy, medication or radiation procedure code	97 (96 to 100)	100 (100 to 100)	83 (80 to 85)

PPV, positive predictive value.

DISCUSSION

Summary of findings

To our knowledge, this is the first review that systematically addressed the validity of algorithms related to breast cancer diseases in administrative databases. Using several medical literature databases, we have identified a significant number of validation studies related to breast cancer disease. Because of the heterogeneity of the results due to the different settings of each included study, we decided to present them in a descriptive manner rather than aggregate them by means of a meta-analysis. Findings from this review suggest that algorithms based on ICD-9 or ICD-10 codes related to breast cancer are accurate in identifying subjects with invasive breast cancer when the diagnosis is

in primary position and the algorithm is based on incident cases. Sixty-seven per cent of the studies reported sensitivities or PPVs higher than 80% for inpatient breast cancer code at the initial presentation. The addition of other fields such as surgical procedures, chemotherapy or radiation therapy, outpatient data and physician claims may improve the accuracy results but depend on the accuracy measure used. Breast cancer codes in secondary position yielded lower accuracy values.

Quality of primary studies and heterogeneity

The overall quality of the studies included in our review was judged quite good. There are only some concerns about the items of the modified STARD checklist related

Table 5 Range of sensitivities and PPVs stratified by administrative data source, type of ICD code and country of origin

	Range of sensitivities	Range of PPVs
Administrative data source		
Inpatient (primary position only)	53%–99% (18 studies)	15%–98% (19 studies)
Outpatient (outpatient diagnosis only)	9% (1 study)	19% (1 study)
Type of ICD		
ICD-9 (initial algorithm)	53%–97% (15 studies)	15%–98% (16 studies)
ICD-10 (initial algorithm)	69%–99% (3 studies)	57%–86% (3 studies)
Country of origin		
USA (initial algorithm)	53%–97% (12 studies)	15%–96% (13 studies)
Italy (initial algorithm)	74%–85% (2 studies)	90%–91% (2 studies)
France (initial algorithm)	69%–85% (2 studies)	57%–98% (2 studies)
Japan (initial algorithm)	99% (1 study)	66% (1 study)
Australia (initial algorithm)	86% (1 study)	86% (1 study)
Accuracy over time		
Before 2001 (initial algorithm)	57%–97% (7 studies)	74%–96% (9 studies)
After 2000 (initial algorithm)	53%–99% (11 studies)	15%–98% (10 studies)

ICD, International Classification of Disease; PPV, positive predictive value.

to the description of data collection (who identified the patients, who collected data and whether the authors used an a priori data collection form) of which, evaluating the primary studies, we were not able to find these descriptions in the text. However, we do not think that this could significantly affect the results of our review, as it was common to all the studies and it could be related in general to the peculiarity of the studies validating administrative databases that are substantially different from the typical diagnostic accuracy studies.

Regarding reference standard, most of the studies used cancer registries and the confirmation of the cancer disease was based on the presence of the corresponding code within the registry. When medical charts were used as a reference standard, in three studies the diagnosis of carcinoma of the breast was confirmed when there was evidence of a histological documentation of ‘invasive carcinoma of the breast’, ‘intraductal carcinoma (ductal carcinoma in situ) of the breast’ or ‘Paget’s disease of the breast’,^{45 50 51} whereas Fisher *et al*⁴¹ reported that ‘accredited records technicians, blinded to the coding in the original records, reviewed the medical records, selected the supportable diagnoses and procedures and translated them into ICD-9-CM’.

The included studies differed in the geographical area, temporal period, healthcare system, reference standard considered and other factors, and this heterogeneity could explain the variability of the diagnostic accuracy measures. Because of the heterogeneity of the results due to the different settings of each included study, we decided to present them in a descriptive manner rather than aggregate them by means of a meta-analysis.

Prioritising accuracy measures

In assessing the validity of healthcare databases, researchers will need to weigh the relative importance of epidemiological measures and prioritise the accuracy measure that is most important to a particular study. As pointed out by Chuback *et al*,³⁵ for example, contrary to PPV estimates, sensitivity and specificity do not depend on the disease prevalence but can vary across populations. Privileging sensitivity to specificity is relevant in a scenario where identifying all cases with the characteristic of interest is important rather than only those with severe disease characteristics. PPV is generally preferred when one wants to ensure that only the subjects who truly have the condition of interest are included in the study. In our assessment, 19 studies provided PPV measures, 15 of which also measured sensitivity.^{10 38 40–44 46–49 53–55}

Most of these performed an accuracy assessment with the intent to define the incidence of breast or other cancer diseases. Several authors included different variables in their algorithm, including surgical, chemoradiation or radiation treatment, outpatient care, such as physician’s claims in order to obtain algorithms with a balanced value between PPV and sensitivity. While three studies obtained similar values between sensitivity and PPV,^{40 43 55} in six studies^{10 38 42 46 48 54} the initial PPVs were higher than sensitivity and most of these studies had the priority of estimating the incidence of breast cancer disease. Sato *et al*⁴⁹ attributed the gain of optimal sensitivity (90%) and PPV (99%) to the use of both inpatient and outpatient claims data. The authors argue that they might have obtained high sensitivity but low PPV if they had used the outpatient database alone. In two Italian validation studies^{10 38} of regional administrative databases, the combination of

hospital diagnosis together with surgical procedures accurately identified the majority of cases in the cancer registry (PPV 90% and 91%, respectively). In other circumstances, the aims of the studies were substantially methodological. Freeman *et al*,⁴² who aimed at obtaining the optimal combination of predictors, used a logistic regression model using 1992 data from the linked SEER registries. The authors were able to obtain a high sensitivity (90%) with the use of three kinds of claims data (inpatients, outpatients and physician services), but with a loss of PPV (70%) that was probably due to limitations in distinguishing recurrent and secondary cancers. Cooper *et al*³⁹ only investigated the sensitivity of diagnostic and procedural coding for case ascertainment of breast and five other cancer diseases. The authors used two sets of analyses: the first set was the inpatient Medicare claims, which include diagnoses and procedures ICD-9 codes; the second set was the part B claims, which include physician and outpatient data. The first set considered the sensitivity of inpatient first position (68.3%) and the increase in sensitivity provided by including additional fields (other diagnosis (76.1%), surgical (79.1%), part B first position (91%), part B other diagnosis (93.1%), part B surgical code (93.6%)). In the second set of analyses, they considered the sensitivity of part B first position (66%) and included the following additional fields: part B other diagnosis (76.9%), part B surgical (80.9%), inpatient first position (90.9%), inpatient other diagnosis (93%) and inpatient surgical (93.6%).

Conversely, the aim of Nattinger *et al*⁴⁷ was to maintain a high specificity and they proposed a four-step algorithm to identify women with surgically treated incident breast cancer that was applied in both a validation set and a training set. For their objective, they considered cases treated in the ambulatory surgical setting as well as prevalent cases. The authors were able to obtain high specificity (99.9%) with a decrease in sensitivity from 85% to 80% but with a good PPV performance (range 89%–93%). As recognised by the authors, the algorithm may have little usefulness in determining the incidence of breast cancer, but it may be much more relevant for outcome classification.³⁵

Strengths and limitations

Our strengths include the use of comprehensive electronic databases with reference checks of relevant reviews of articles, the use of STARD criteria to assess the quality of reporting of primary studies, transparency based on prepublication of a protocol (online supplementary file 5), the use of detailed and explicit eligibility criteria and the use of duplicate and independent processes for study selection, data abstraction and data interpretation.

We must acknowledge that our assessment was focused on primary breast cancer and we did not take into account diagnosis of metastases due to breast cancer. A recent study that evaluated the accuracy of ICD-9 codes in identifying metastatic breast and other cancer diseases found that the performance of the metastases codes from

Medicare claims data compared with the gold standard of SEER stage was poor and never exceeded 80% for any of the accuracy measures for any stage for any cancer metastatic disease.⁶⁰ Other studies reported similar low values of accuracy and this may misclassify a significant number of patients and lead to a biased assessment of survival.^{22 61 62}

Second breast cancer recurrences and second primary breast cancers are of interest in the epidemiological and outcome research of breast cancer. In our assessment, we did not consider studies that used algorithms to identify recurrences and second breast cancer events. A recent study assessed several algorithms to identify second breast cancer events following early stage invasive breast cancer and found high accuracy measures.⁶³ In addition, we were not able to consider articles that were not written in English and this may have introduced language bias. In addition, despite the comprehensive nature of our search, a few pertinent articles may have been missed given that some identified articles did not use the term 'administrative database' as a subject heading, and the term is not recognised as a MeSH by Medline. Indeed, we were able to identify four primary studies^{54–57} using the Cited-By' tools in PubMed, Google Scholar or checking the reference of included studies. Fourth, the knowledge and experience of the ICD-9/ICD-10 coders could have influenced the quality of breast cancer case definition in each study, and consequently the results presented in our review could be biased by this factor. Finally, we emphasise that the applicability of validation studies depends much on the methods used to identify subjects with the condition of interest to validate the algorithm because this may influence the disease prevalence, and the generalisability of the subjects characteristics as well as the diagnostic accuracy measures. Hence, the generalisability of a database is limited to the setting in which the validation has been performed.⁶⁴ For example, while Medicare covers the elderly^{41 42 47 55 59 61} and Medicaid covers indigent and other particular group of patients groups,^{44 57} the US Healthcare, is an independent practice association model, that may represent patient populations of a relatively higher socioeconomic class.^{50 51} Hence, inference from these validated databases cannot be made to those who despite residing in the same area of the residents registered in the above reported systems but do not benefit from them or to subjects aged 64 years or less as is in most cases of the Medicare system. Conversely, the database in Italy^{10 38} and France^{40 54} where the provision of healthcare is universally provided to residents, the applicability of the results from the validated databases is adequate, although it cannot be extended at a national level. Finally, we found a study that validated data from a single institution in Japan and as acknowledged by the authors it is unclear whether the accuracy results can be directly applicable to other hospitals.⁴⁹

CONCLUSION

In summary we conclude that, based on the retrieved evidence, administrative databases can be employed to identify primary breast cancer. The best algorithm suggested is ICD-9 or ICD-10 codes located in primary position. Caution should be used when surgical procedures, chemotherapy, radiation therapy or outpatient data and physician claims are added to the algorithm. We believe that our findings will help researchers that would like to validate breast cancer ICD-9 or ICD-10 codes in administrative databases using either cancer registry or medical charts.

Acknowledgements The authors would like to thank Kathy Mahan for editing the manuscript.

Contributors IA, AM, GG, DG, MF conceived and designed the study; EB, VS, AG, FC, MO, IA and AM were involved in the data acquisition; IA, AM, DS, MF and GG analysed and interpreted the data and IA, EB, MO, GG, DS, VS, AG, FC, MF and AM contributed in the drafting and revising the study and have approved submission of the final version of the article. AM is the guarantor of the review.

Funding This systematic review protocol was developed within the D.I.V.O. project (Realizzazione di un Database Interregionale Validato per l'Oncologia quale strumento di valutazione di impatto e di appropriatezza delle attività di prevenzione primaria e secondaria in ambito oncologico) supported by funding from the National Centre for Disease Prevention and Control (CCM 2014), Ministry of Health, Italy.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The authors will give full access to our database that gathered data of individual studies included in this review. The request must be done by sending an email to amontedori@regione.umbria.it.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Sullivan R, Peppercorn J, Sikora K, *et al.* Delivering affordable cancer care in high-income countries. *Lancet Oncol* 2011;12:933–80.
- Ginsburg O, Bray F, Coleman MP, *et al.* The global burden of women's cancers: a grand challenge in global health. *Lancet* 2017;389:847–60.
- Jemal A, Center MM, DeSantis C, *et al.* Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* 2010;19:1893–907.
- Chen HF, Liu MD, Chen P, *et al.* Risks of Breast and Endometrial Cancer in Women with Diabetes: A Population-Based Cohort Study. *PLoS One* 2013;8:e67420.
- Escribà JM, Pareja L, Esteban L, *et al.* Trends in the surgical procedures of women with incident breast cancer in Catalonia, Spain, over a 7-year period (2005–2011). *BMC Res Notes* 2014;7:587.
- Montero AJ, Eapen S, Gorin B, *et al.* The economic burden of metastatic breast cancer: a U.S. managed care perspective. *Breast Cancer Res Treat* 2012;134:815–22.
- Earle CC, Venditti LN, Neumann PJ, *et al.* Who gets chemotherapy for metastatic lung cancer? *Chest* 2000;117:1239–46.
- Song X, Zhao Z, Barber B, *et al.* Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. *Curr Med Res Opin* 2011;27:123–30.
- Vachon B, Désorcy B, Gaboury I, *et al.* Combining administrative data feedback, reflection and action planning to engage primary care professionals in quality improvement: qualitative assessment of short term program outcomes. *BMC Health Serv Res* 2015;15:391.
- Yuen E, Louis D, Cisbani L, *et al.* Using administrative data to identify and stage breast cancer cases: implications for assessing quality of care. *Tumori* 2011;97:428–35.
- Whyte JL, Engel-Nitz NM, Teitelbaum A, *et al.* An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data. *Med Care* 2015;53:e49–e57.
- Bremner KE, Krahn MD, Warren JL, *et al.* An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. *Palliat Med* 2015;29:918–28.
- Mittmann N, Liu N, Porter J, *et al.* Utilization and costs of home care for patients with colorectal cancer: a population-based study. *CMAJ Open* 2014;2:E11–17.
- Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol* 2005;58:323–37.
- Schulman KL, Berenson K, Tina Shih YC, *et al.* A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR oncology good outcomes research practices working group. *Value Health* 2013;16:655–69.
- Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. *JAMA* 2012;307:1433–5.
- West SL, Strom BL, Poole C. *Validity of Pharmacoepidemiologic Drug and Diagnosis Data*, in *Pharmacoepidemiology*: John Wiley & Sons, Ltd, 2007:709–65.
- Cox E, Martin BC, Van Staa T, *et al.* Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. *Value Health* 2009;12:1053–61.
- Senkus E, Kyriakides S, Ohno S, *et al.* ESMO Guidelines Committee. *Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. *Ann Oncol* 2015;26(suppl 5):v8–30.
- Weycker D, Edelsberg J, Kartashov A, *et al.* Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. *Chemotherapy* 2012;58:8–18.
- Vera-Llonch M, Weycker D, Glass A, *et al.* Healthcare costs in patients with metastatic lung cancer receiving chemotherapy. *BMC Health Serv Res* 2011;11:305.
- Nordstrom BL, Whyte JL, Stolar M, *et al.* Identification of metastatic cancer in claims data. *Pharmacoepidemiol Drug Saf* 2012;21(Suppl 2):21–8.
- Abraha I, Serraino D, Giovannini G, *et al.* Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol. *BMJ Open* 2016;6:e010547.
- Montedori A, Bidoli E, Serraino D, *et al.* Accuracy of lung cancer ICD-9-CM codes in Umbria, Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study. *BMJ Open* 2018;8:e020628.
- Orso M, Serraino D, Abraha I, *et al.* Validating malignant melanoma ICD-9-CM codes in Umbria, ASL Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study. *BMJ Open* 2018;8:e020631.
- Abraha I, Giovannini G, Serraino D, *et al.* Validity of breast, lung and colorectal cancer diagnoses in administrative databases: a systematic review protocol. *BMJ Open* 2016;6:e010409.
- Montedori A, Abraha I, Chiatti C, *et al.* Validity of peptic ulcer disease and upper gastrointestinal bleeding diagnoses in administrative databases: a systematic review protocol. *BMJ Open* 2016;6:e011776.
- Rimland JM, Abraha I, Luchetta ML, *et al.* Validation of chronic obstructive pulmonary disease (COPD) diagnoses in healthcare databases: a systematic review protocol. *BMJ Open* 2016;6:e011777.
- Cozzolino F, Abraha I, Orso M, *et al.* Protocol for validating cardiovascular and cerebrovascular ICD-9-CM codes in healthcare administrative databases: the Umbria Data Value Project. *BMJ Open* 2017;7:e013785.
- Benchimol EI, Manuel DG, To T, *et al.* Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. *J Clin Epidemiol* 2011;64:821–9.
- Carnahan RM, Moores KG. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned. *Pharmacoepidemiol Drug Saf* 2012;21:82–9.

32. McPheeters ML, Sathe NA, Jerome RN, *et al.* Methods for systematic reviews of administrative database studies capturing health outcomes of interest. *Vaccine* 2013;31(Suppl 10):K2–6.
33. Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.
34. Shamseer L, Moher D, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
35. Chubak J, Pocobelli G, Weiss NS. Tradeoffs between accuracy measures for electronic health care data algorithms. *J Clin Epidemiol* 2012;65:343–9.
36. Dean BB, Lam J, Natoli JL, *et al.* Review: use of electronic medical records for health outcomes research: a literature review. *Med Care Res Rev* 2009;66:611–38.
37. Bossuyt PM, Reitsma JB, Bruns DE, *et al.* Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. *Ann Intern Med* 2003;138:40–4.
38. Baldi I, Vicari P, Di Cuonzo D, *et al.* A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. *J Clin Epidemiol* 2008;61:373–9.
39. Cooper GS, Yuan Z, Stange KC, *et al.* The sensitivity of Medicare claims data for case ascertainment of six common cancers. *Med Care* 1999;37:436–44.
40. Couris CM, Polazzi S, Olive F, *et al.* Breast cancer incidence using administrative data: correction with sensitivity and specificity. *J Clin Epidemiol* 2009;62:660–6.
41. Fisher ES, Whaley FS, Krushat WM, *et al.* The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. *Am J Public Health* 1992;82:243–8.
42. Freeman JL, Zhang D, Freeman DH, *et al.* An approach to identifying incident breast cancer cases using Medicare claims data. *J Clin Epidemiol* 2000;53:605–14.
43. Kemp A, Preen DB, Saunders C, *et al.* Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia. *BMC Med Res Methodol* 2013;13:17.
44. Koroukian SM, Cooper GS, Rimm AA. Ability of Medicaid claims data to identify incident cases of breast cancer in the Ohio Medicaid population. *Health Serv Res* 2003;38:947–60.
45. Leung KM, Hasan AG, Rees KS, *et al.* Patients with newly diagnosed carcinoma of the breast: validation of a claim-based identification algorithm. *J Clin Epidemiol* 1999;52:57–64.
46. McClish DK, Penberthy L, Whittemore M, *et al.* Ability of Medicare claims data and cancer registries to identify cancer cases and treatment. *Am J Epidemiol* 1997;145:227–33.
47. Nattinger AB, Laud PW, Bajorunaite R, *et al.* An algorithm for the use of Medicare claims data to identify women with incident breast cancer. *Health Serv Res* 2004;39(Pt 1):1733–50.
48. Penberthy L, *et al.* The added value of claims for cancer surveillance: results of varying case definitions. *Med Care* 2005;43:705–12.
49. Sato I, Yagata H, Ohashi Y. The accuracy of Japanese claims data in identifying breast cancer cases. *Biol Pharm Bull* 2015;38:53–7.
50. Solin LJ, Legorreta A, Schultz DJ, *et al.* Analysis of a claims database for the identification of patients with carcinoma of the breast. *J Med Syst* 1994;18:23–32.
51. Solin LJ, MacPherson S, Schultz DJ, *et al.* Evaluation of an algorithm to identify women with carcinoma of the breast. *J Med Syst* 1997;21:189–99.
52. Warren JL, Feuer E, Potosky AL, *et al.* Use of Medicare hospital and physician data to assess breast cancer incidence. *Med Care* 1999;37:445–56.
53. Warren JL, Riley GF, McBean AM, *et al.* Use of Medicare data to identify incident breast cancer cases. *Health Care Financ Rev* 1996;18:237–46.
54. Ganry O, Taleb A, Peng J, *et al.* Evaluation of an algorithm to identify incident breast cancer cases using DRGs data. *Eur J Cancer Prev* 2003;12:295–9.
55. McBean AM, Warren JL, Babish JD. Measuring the incidence of cancer in elderly Americans using Medicare claims data. *Cancer* 1994;73:2417–25.
56. Setoguchi S, Solomon DH, Glynn RJ, *et al.* Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. *Cancer Causes Control* 2007;18:561–9.
57. Wang PS, Walker AM, Tsuang MT, *et al.* Finding incident breast cancer cases through US claims data and a state cancer registry. *Cancer Causes Control* 2001;12:257–65.
58. Ramsey SD, Scoggins JF, Blough DK, *et al.* Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. *J Manag Care Pharm* 2009;15:659–68.
59. Penberthy L, McClish D, Manning C, *et al.* The added value of claims for cancer surveillance: results of varying case definitions. *Med Care* 2005;43:705–12.
60. Chawla N, Yabroff KR, Mariotto A, *et al.* Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. *Ann Epidemiol* 2014;24:666–72.
61. Cooper GS, Yuan Z, Stange KC, *et al.* The utility of Medicare claims data for measuring cancer stage. *Med Care* 1999;37:706–11.
62. Thomas SK, Brooks SE, Mullins CD, *et al.* Use of ICD-9 coding as a proxy for stage of disease in lung cancer. *Pharmacoeconom Drug Saf* 2002;11:709–13.
63. Chubak J, Yu O, Pocobelli G, *et al.* Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. *J Natl Cancer Inst* 2012;104:931–40.
64. Abraha I, Orso M, Grilli P, *et al.* The Current State of Validation of Administrative Healthcare Databases in Italy: A Systematic Review. *Int J Stat Med Res* 2014;3:309–20.